Authors: Giannis D, allen SL, Tsang J, Flint S, Pinhasov T, Williams S PMID: 33824972 PMCID: PMC8032474 DOI: 10.1182/blood.2020010529 Abstract Thromboembolic events, including venous thromboembolism (VTE) and arterial thromboembolism (ATE), and mortality from subclinical thrombotic events occur frequently in coronavirus disease 2019 (COVID-19) inpatients. Whether the risk extends postdischarge has been controversial. Our prospective registry [...]

Authors: Chen CX, Wang JJ, Li H, Yuan LT, Gale RP PMID: 33990684 PMCID: PMC8119232 DOI: 10.1038/s41375-021-01266-6 Abstract We analyzed reports on safety and efficacy of JAK-inhibitors in patients with coronavirus infectious disease-2019 (COVID-19) published between January 1st and March 6th 2021 using the Newcastle-Ottawa and Jadad scales for quality assessment. We used disease severity [...]

Authors: Zhang J, Rao X, Li Y, Zhu Y, Liu G, Guo G et al. PMID: 34106642 PMCID: PMC8133047 DOI: 10.1097/MD.0000000000025876 Abstract Background: Patients infected with a virus usually lack vitamin C. High-dose vitamin C has an antiviral effect, and has been used by several researchers to treat COVID-19 by intravenous infusion, achieving good results. [...]

Authors: Reiter RR, Sharma R, Castillo R, Marik PE, Rodriguez AD, Cardinali DP Abstract Two highly relevant studies related to SARS-CoV-2 and coronavirus disease (COVID-19) and supporting the use of melatonin to prevent and treat this serious infection were published recently. Campos-Codo and colleagues [1] documented experimentally their claim that drugs which specifically target [...]

Authors: Jeronimo CM, Farias ME, Almeida FF, Sampaio VS, Alexandre MA, Melo GC PMID: 32785710 PMCID: PMC7454320 DOI: 10.1093/cid/ciaa1177 Abstract Background: Steroid use for coronavirus disease 2019 (COVID-19) is based on the possible role of these drugs in mitigating the inflammatory response, mainly in the lungs, triggered by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). [...]

Authors: Rose J Abstract Following the global roll-out and administration of the Pfizer/BioNTech (BNT1 62b2) and Moderna (mRNA-1 273) COVID-1 9 vaccines 1 on December 1 7, 2020 in the United States, and of the Janssen COVID-1 9 Vaccine PF (produced by Johnson & Johnson) on April 1 st, 2021 , tens of thousands [...]

Authors: Janiri D, Carfi A, Kotzalidis GD, Bernabei R PMID: 33599709 PMCID: PMC7893542 DOI: 10.1001/jamapsychiatry.2021.0109 Abstract This cross-sectional study analyzes characteristics associated with posttraumatic stress disorder in patients after severe coronavirus disease 2019 (COVID-19). Keywords: COVID-19, PTSD, post traumatic stress disorder Source: https://pubmed.ncbi.nlm.nih.gov/33599709/ Archive: https://archive.is/xmUUh

Authors: Trahtemberg U, Fritzler MJ PMID: 33928414 PMCID: PMC8084710 DOI: 10.1007/s00134-021-06408-z Abstract Coronavirus disease 2019 (COVID-19) has similarities to systemic autoimmune conditions, including an association with increased incidence of autoantibodies, including those directed toward cytokines. However, reports to date lack longitudinal assessments and have inadequate controls (i.e., comparison to different severities within COVID-19 or to [...]

Authors: Loucera C, Pena-Chilet M, Esteban-Medina M, Villegas R, Tunez I doi: https://doi.org/10.1101/2021.04.27.21255937 Abstract Background COVID-19 is a major worldwide health problem because of acute respiratory distress syndrome, and mortality. Several lines of evidence have suggested a relationship between the vitamin D endocrine system and severity of COVID-19. Methods We present a retrospective survival study [...]

Authors: Chamie-Quintero JJ, Hibberd JA, Scheim DE doi: https://doi.org/10.5061/dryad.dv41ns1xr Abstract Objective. We aimed to identify mortality trends associated with COVID-19 deaths in Peru during April through November 2020, when mass treatments with ivermectin (IVM), a drug of Nobel Prize-honored distinction, were autonomously deployed at different times and to different extents in [...]